Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) delivers targeted therapies for central nervous system disorders through its precision medicine approach. This news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access timely press releases covering trial results, platform innovations (including Cerebrum™ small molecule and Solidus™ ASO technologies), and progress in treating epilepsy, depression, and essential tremor. Our curated collection ensures you stay informed about PRAX's advancements in addressing neuronal excitation-inhibition imbalances through genetic insights.
Discover updates categorized by clinical trial phases, collaborative research initiatives, and therapeutic area developments. Bookmark this page for streamlined access to Praxis' latest scientific achievements and corporate announcements in the CNS biopharmaceutical space.
Praxis Precision Medicines (Nasdaq: PRAX) announced that its Compensation Committee has granted non-qualified stock options and restricted stock units to a new non-executive employee under its 2024 Inducement Plan. This plan is used to attract new talent under Nasdaq Listing Rule 5635(c)(4). The grants include stock options to purchase 300 shares and restricted stock units covering 225 shares of common stock. The exercise price of the options is $47.05 per share, matching the closing price on the Nasdaq Global Select Market as of June 3, 2024. The stock options will vest over four years, with 25% vesting after the first year and the remaining vesting equally over the subsequent three years. Similarly, the restricted stock units will vest in four equal annual installments, contingent on the employee’s continued employment.
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, announced its participation in three upcoming investor conferences. Praxis will attend the H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on May 20, 2024, with a live webcast available. The company will also be at the Mizuho Securities USA Neuroscience Summit in Boston on May 21, 2024. Additionally, Praxis will join the Jefferies Global Healthcare Conference in New York on June 6, 2024, with a live webcast available. Replay of the webcasts will be accessible on the company's website for 90 days.
Praxis Precision Medicines, Inc. provided a corporate update and reported financial results for Q1 2024. The company plans to initiate two efficacy studies for PRAX-628, continues recruitment for Essential3 trials, and completed a public offering, resulting in cash of $451.2 million. Key developments include positive results for PRAX-628, expected topline results for Essential3 in H2 2024, and PRAX-562 Phase 2 EMBOLD study results in Q3 2024. Praxis aims to submit a NDA for ulixacaltamide in 2025 and is progressing with Elsunersen for SCN2A GoF DEEs.
Praxis Precision Medicines, Inc. will release its first quarter 2024 financial results on May 13, 2024. The company focuses on developing therapies for CNS disorders related to neuronal excitation-inhibition imbalance.
Praxis Precision Medicines, Inc. announced the granting of non-qualified stock options and restricted stock units to six new non-executive employees under the 2024 Inducement Plan. The options have an exercise price of $55.16 per share and will vest over four years, while the restricted stock units will vest in four equal annual installments. This move aims to attract and retain top talent for the company.
FAQ
What is the current stock price of Praxis Precision Medicines (PRAX)?
What is the market cap of Praxis Precision Medicines (PRAX)?
